By Billy Candra 
Cambridge, UK – A groundbreaking study led by University of Cambridge researchers has revealed that bilateral salpingo-oophorectomy (BSO) – the surgical removal of the ovaries and fallopian tubes – not only dramatically reduces the risk of ovarian cancer in women with particular BRCA1 and BRCA2 genetic variants but also leads to a substantial reduction in their risk of early death from any cause, including a lower likelihood of developing a second primary cancer. Crucially, this significant survival benefit appears to be achieved without an increased risk of serious long-term side effects such as heart disease, stroke, or depression, challenging previous general population assumptions about early menopause.
Understanding the BRCA Challenge: A Genetic Predisposition to Cancer
The BRCA1 and BRCA2 genes are integral components of the human body’s DNA repair machinery. They are tumour suppressor genes, meaning their normal function helps prevent the uncontrolled growth of cells that can lead to cancer. However, specific inherited mutations (also known as pathogenic variants or PVs) in these genes significantly impair their ability to repair damaged DNA. This genetic vulnerability dramatically increases an individual’s lifetime risk of developing several cancers, most notably breast and ovarian cancers, but also prostate cancer in men, pancreatic cancer, and melanoma.
For women carrying these pathogenic variants, the statistics are stark. A woman with a BRCA1 mutation faces up to a 72% lifetime risk of breast cancer and a 44% lifetime risk of ovarian cancer. For BRCA2 mutation carriers, the risks are similarly elevated, with up to a 69% lifetime risk of breast cancer and a 17% lifetime risk of ovarian cancer. These figures are substantially higher than those in the general population, where the lifetime risk for breast cancer is around 13% and for ovarian cancer is just over 1%.
The diagnosis of breast cancer in a BRCA carrier often comes at a younger age, and the tumours can sometimes be more aggressive, such as triple-negative breast cancer frequently seen in BRCA1 carriers. While advancements in breast cancer treatment have improved outcomes, the specter of ovarian cancer remains a significant concern. Ovarian cancer is notoriously difficult to detect early due to its often vague symptoms, leading to late-stage diagnoses and a grim prognosis, making preventative strategies paramount.
Bilateral Salpingo-Oophorectomy: A Preventative Measure with Unanswered Questions
For decades, BSO has been offered as a highly effective preventative measure against ovarian cancer for women carrying BRCA1 and BRCA2 mutations. Previous research has consistently demonstrated that this procedure can reduce the risk of developing ovarian cancer by as much as 80% in this high-risk population. Guidelines recommend BSO at a relatively early age: typically between 35 and 40 years for BRCA1 carriers, and between 40 and 45 years for BRCA2 carriers, reflecting the differing age-related risks associated with each gene.
Despite its proven efficacy in preventing ovarian cancer, BSO involves the removal of the body’s primary source of oestrogen, inducing surgical menopause. This abrupt onset of menopause, often years before natural menopause, has raised concerns about potential unintended long-term consequences. These concerns include an increased risk of cardiovascular disease, osteoporosis, cognitive decline, and psychological impacts such as depression, all linked to the sudden decline in oestrogen levels. For BRCA1 and BRCA2 carriers with a history of breast cancer, the situation is further complicated, as many are advised against hormone replacement therapy (HRT) due to fears of increasing breast cancer recurrence risk, leaving them to manage menopausal symptoms without typical pharmacological support. The overall impact of BSO on total survival and general health outcomes for BRCA carriers, particularly those who have already battled breast cancer, remained a critical area of uncertainty.
Ethical Challenges and Innovative Research Design
Traditionally, the "gold standard" for evaluating the benefits and risks of medical interventions is a randomised controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention (e.g., BSO) or a control (e.g., no BSO), allowing researchers to compare outcomes with high confidence. However, conducting an RCT for BSO in women with BRCA1 and BRCA2 variants would be ethically indefensible. Randomly assigning these women to a "no BSO" group would knowingly expose them to a substantially and unacceptably higher risk of developing deadly ovarian cancer, a direct contravention of the ethical principle of "do no harm."
To overcome this formidable ethical barrier, a pioneering team at the University of Cambridge, in a crucial collaboration with the National Disease Registration Service (NDRS) within NHS England, adopted an innovative approach. They leveraged the vast repositories of electronic health records and genetic testing laboratory data, meticulously collected and curated by the NDRS. This allowed them to conduct a large-scale, observational study, examining the long-term outcomes of BSO among BRCA1 and BRCA2 pathogenic variant (PV) carriers who had previously been diagnosed with breast cancer. The findings of this landmark study, described as the first large-scale investigation of its kind, were published today in the prestigious journal The Lancet Oncology.
The Study’s Cohort and Key Findings
The research team meticulously identified a cohort of 3,400 women across England carrying either a BRCA1 or BRCA2 cancer-causing variant, with approximately 1,700 women for each variant. Within this cohort, around 850 of the BRCA1 carriers and 1,000 of the BRCA2 carriers had undergone BSO surgery. The study’s design allowed for a median follow-up period of 5.5 years, providing robust data on long-term outcomes.
The results were compelling and unequivocally positive:
- Significant Reduction in Early Death: Women who underwent BSO were approximately half as likely to die from cancer or any other cause over the follow-up period compared to those who did not have the surgery. This finding underscores a profound overall survival benefit.
- Variant-Specific Benefits: The reduction in mortality was more pronounced in BRCA2 carriers, who experienced a 56% lower risk of early death, compared to BRCA1 carriers, who saw a 38% reduction. While the exact reasons for this difference warrant further investigation, it could be influenced by the typically earlier onset and often more aggressive nature of breast cancers associated with BRCA1 mutations, or distinct biological pathways through which BSO impacts overall survival for each gene.
- Reduced Risk of Second Cancers: Beyond the prevention of ovarian cancer, women who underwent BSO also demonstrated a significant 40% lower risk of developing a second primary cancer. This finding suggests a broader protective effect of BSO, potentially related to hormonal changes or other systemic impacts that mitigate overall cancer risk in this vulnerable population.
- No Increased Risk of Adverse Long-Term Outcomes: Crucially, the researchers found no statistically significant link between BSO and an increased risk of other long-term health outcomes such as heart disease, stroke, or depression. This finding directly contrasts with some previous studies in the general population that had suggested an association between surgical menopause and an elevated risk of these conditions. This is a vital piece of information, offering considerable reassurance to both patients and clinicians.
While the observational nature of the study means researchers cannot state with 100% certainty that BSO causes this reduction in risk, the strength and consistency of the evidence strongly point towards this conclusion. The careful methodology, large cohort size, and comprehensive data integration lend significant weight to these findings.
Expert Perspectives and Clinical Significance
Hend Hassan, a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, and the study’s first author, articulated the prevailing uncertainty prior to this research. "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes," she explained. "Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression."
Professor Antonis Antoniou, from the Department of Public Health and Primary Care and the study’s senior author, highlighted the immediate clinical impact of these findings. "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation," he stated. This study provides concrete, large-scale data to underpin discussions between healthcare providers and patients, moving beyond the previous uncertainties regarding overall health and survival for breast cancer survivors with BRCA mutations considering BSO. It empowers women to weigh the known benefits against previous theoretical risks with greater clarity.
Addressing Health Disparities: A Call to Action
The study also shed light on concerning disparities in BSO uptake. The data revealed that most women undergoing BSO were white. Black and Asian women were found to be approximately half as likely to have BSO compared to white women. Furthermore, women residing in less deprived areas were more likely to undergo BSO than those in the most deprived categories.
These findings underscore significant health inequities that demand urgent attention. Hend Hassan emphasized this point, adding, "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women."
Several factors could contribute to these disparities:
- Access to Care and Genetic Testing: Socioeconomic status and geographic location often dictate access to specialized genetic counselling and surgical services. Women in deprived areas may face greater barriers in terms of transportation, childcare, time off work, and financial constraints.
- Cultural and Linguistic Barriers: For Black and Asian women, cultural factors, language barriers, and varying levels of health literacy or trust in the healthcare system can impede access to information, understanding of risks and benefits, and ultimately, uptake of preventative surgeries.
- Awareness and Education: There may be a lack of awareness within certain communities about the importance of genetic testing for BRCA mutations, or about the life-saving potential of BSO once a mutation is identified. Healthcare providers also need to be equipped to address these disparities actively.
- Implicit Bias: Unconscious biases within the healthcare system can sometimes lead to differential recommendations or access to care based on race, ethnicity, or socioeconomic status.
Addressing these disparities will require multifaceted public health interventions, including targeted outreach programs, culturally sensitive educational materials, improved access to genetic counselling and testing in underserved communities, and training for healthcare professionals on health equity. The goal must be to ensure that all eligible women, regardless of their background or socioeconomic status, have equal access to this life-saving procedure.
The Power of Data: NHS Datasets and Future Research
Professor Antoniou also praised the instrumental role of the NHS datasets in this research. "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research," he noted. The ability to link comprehensive electronic health records with genetic testing data across a national health service provides an invaluable resource for researchers, enabling large-scale, real-world evidence generation that would otherwise be impossible or unethical to obtain. This approach serves as a powerful model for future research, particularly in areas where traditional RCTs are not feasible.
While this study provides robust evidence, further research will continue to refine our understanding. Longer-term follow-up of these cohorts will be crucial to confirm the sustained benefits and continued absence of adverse effects over many decades. Investigations into the optimal timing of BSO for specific subgroups, the precise mechanisms behind the reduction in second primary cancers, and the impact of various menopausal symptom management strategies (including carefully selected HRT for non-breast cancer cases) will also be important.
Broader Implications and Ongoing Efforts
This research represents a significant advance in the management of women with BRCA1 and BRCA2 mutations, especially those who have already faced a breast cancer diagnosis. It provides clear, evidence-based reassurance regarding the overall survival benefits of BSO, solidifying its role as a critical preventative measure. By debunking concerns about increased risks of heart disease, stroke, and depression, the study empowers women and their clinicians to make more confident, informed decisions.
The research was generously funded by Cancer Research UK, with additional support from the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre, underscoring the commitment to advancing cancer care through rigorous scientific inquiry.
Beyond this study, the broader efforts in cancer research continue to push boundaries. The University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for a new hospital, the Cambridge Cancer Research Hospital. This ambitious project, a partnership with Cambridge University Hospitals NHS Foundation Trust, aims to revolutionize the diagnosis and treatment of cancer for patients across the East of England. Critically, the cutting-edge research conducted within its walls promises to yield discoveries that will transform the lives of cancer patients not only across the UK but globally, reinforcing the vital link between clinical care and groundbreaking scientific investigation. This latest study from Cambridge is a testament to that enduring commitment.
